Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease

<p>BERWYN, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) — Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last patient last visit in the phase III study of its lead candidate buntanetap in patients with early Parkinson’s disease (PD). Topline data results are expected in January 2024. “We […]</p>
<p>The post <a href="https://forextv.com/top-news/annovis-bio-announces-last-patient-last-visit-in-the-phase-iii-study-of-buntanetap-in-parkinsons-disease/">Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>